Diane F Jelinek, PhD

Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Little, R. F., Erba, H., Stone, R. M., Litzow, M. & 1 others, Tallman, M., Aug 1 2019, In : The New England journal of medicine. 381, 5, p. 432-443 12 p.

Research output: Contribution to journal › Article

B-Cell Chronic Lymphocytic Leukemia

Disease-Free Survival

Confidence Intervals

Immunoglobulin Heavy Chains

Cyclophosphamide

Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

Tschumper, R. C., Shanafelt, T. D., Kay, N. E. & Jelinek, D. F., Jan 1 2019, In : Oncotarget. 10, 1, p. 60-75 16 p.

Research output: Contribution to journal › Article

Long Noncoding RNA

B-Cell Chronic Lymphocytic Leukemia

Disease Progression

Immunoglobulin Heavy Chains

Biological Phenomena

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain

Walters, D. K., Arendt, B. K., Tschumper, R. C., Wu, X. & Jelinek, D. F., Jan 1 2018, In : Experimental Hematology. 57, p. 42-49.e1

Research output: Contribution to journal › Article

Clustered Regularly Interspaced Short Palindromic Repeats

Immunoglobulin Heavy Chains

Multiple Myeloma

Immunoglobulin A

Cell Line

5 Citations (Scopus)

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy

Baliakas, P., Mattsson, M., Hadzidimitriou, A., Minga, E., Agathangelidis, A., Sutton, L. A., Scarfo, L., Davis, Z., Yan, X. J., Plevova, K., Sandberg, Y., Vojdeman, F. J., Tzenou, T., Chu, C. C., Veronese, S., Mansouri, L., Smedby, K. E., Giudicelli, V., Nguyen-Khac, F., Panagiotidis, P. & 20 others, Juliusson, G., Anagnostopoulos, A., Lefranc, M. P., Trentin, L., Catherwood, M., Montillo, M., Niemann, C. U., Langerak, A. W., Pospisilova, S., Stavroyianni, N., Chiorazzi, N., Oscier, D., Jelinek, D. F., Shanafelt, T., Darzentas, N., Belessi, C., Davi, F., Ghia, P., Rosenquist, R. & Stamatopoulos, K., Mar 23 2018, In : Haematologica. 103, 4, p. e158-e161

Research output: Contribution to journal › Letter

B-Cell Chronic Lymphocytic Leukemia

Survival

Therapeutics

7 Citations (Scopus)

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

Larsen, J. T., Shanafelt, T. D., Leis, J. F., Laplant, B., Call, T., Pettinger, A., Hanson, C., Erlichman, C., Habermann, T. M., Reeder, C., Nikcevich, D., Bowen, D., Conte, M., Boysen, J., Secreto, C., Lesnick, C., Tschumper, R., Jelinek, D. F., Kay, N. E. & Ding, W. D., 2017, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journal › Article

B-Cell Chronic Lymphocytic Leukemia

Maximum Tolerated Dose

Safety

Febrile Neutropenia

Exanthema